Paxlovid Tablet

Yes, Paxlovid is an FDA-approved medicine; it was FDA-approved on May 25, 2023. Paxlovid is used for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults who are at high risk for progression to severe COVID-19, including hospitalization or death.

Paxlovid is also available under an Emergency Use Authorisation (EUA) to treat patients 12 to 18 years old for mild-to-moderate COVID-19 who are at high risk for progression to severe COVID-19, including hospitalization or death.

Paxlovid is not approved for use as pre-exposure or post-exposure prophylaxis for the prevention of COVID-19 or prevention of Long COVID.

Common Paxlovid side effects include a bad taste or change in taste, diarrhea, headache, vomiting, stomach pain, nausea, or high blood pressure.

Serious Paxlovid side effects

Get emergency medical help if you have signs of an allergic reaction (hives, difficulty breathing, swelling in your face or throat) or a severe skin reaction (fever, sore throat, burning eyes, skin pain, red or purple skin rash with blistering and peeling).

Call your doctor at once if you have:

• liver problems symptoms include loss of appetite, stomach pain (upper right side), tiredness, itching, dark urine, clay-colored stools, jaundice (yellowing of the skin or eyes).

Ritonavir affects your immune system, which may cause certain side effects (even weeks or months after you've taken nirmatrelvir and ritonavir). Tell your doctor if you have:

• signs of a new infection--fever, night sweats, swollen glands, cold sores, cough, wheezing, diarrhea, weight loss;
• trouble speaking or swallowing, problems with balance or eye movement, weakness or prickly feeling; or
• swelling in your neck or throat (enlarged thyroid), menstrual changes, impotence.

Paxlovid works as nirmatrelvir, is an antiviral medication that stops the virus from multiplying. Nirmatrelvir is a SARS-CoV-2 main protease (Mpro) inhibitor (also known as SARS-CoV2 3CL protease inhibitor) that works by inhibiting viral replication in the early stages of the disease to prevent progression to severe COVID-19.